Article
Oncology
Joshua F. Zeidner, Daniel J. Lee, Mark Frattini, Gil D. Fine, Judy Costas, Kathryn Kolibaba, Stephen P. Anthony, David Bearss, B. Douglas Smith
Summary: Alvocidib, when combined with 7+3 induction therapy, shows promising clinical activity in newly diagnosed acute myeloid leukemia patients, indicating the potential for further investigation of Alvocidib combinations in this population.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Beata Holkova, Danielle Shafer, Victor Yazbeck, Sandeep Dave, Prithviraj Bose, Mary Beth Tombes, Ellen Shrader, Wen Wan, Dipankar Bandyopadhyay, Caryn Weir, Elizabeth B. Collins, Amanda Garnett, Maciej Kmieciak, John D. Roberts, Guillermo Garcia-Manero, Steven Grant
Summary: This study reports the results of a phase 1 dose-escalation study of belinostat and bortezomib in adult patients with acute leukemia and myelodysplastic syndrome. The treatment strategy showed limited activity in the population studied, but some patients exhibited good responses, indicating the need for further investigation into predictive factors for exceptional responses.
LEUKEMIA & LYMPHOMA
(2021)
Article
Oncology
Maria Victoria Mateos, Felipe Prosper, Jesus Martin Sanchez, Enrique M. Ocio, Albert Oriol, Cristina Motllo, Jean-Marie Michot, Isidro Jarque, Rebeca Iglesias, Maria Sole, Sara Martinez, Carmen Kahatt, Salvador Fudio, Gema Corral, Ali Zeaiter, Lola Montilla, Vincent Ribrag
Summary: The triple combination of plitidepsin, BTZ, and DXM showed moderate activity and acceptable safety in adult patients with relapsed/refractory multiple myeloma.
Article
Oncology
Johnny Duerinck, Julia Katharina Schwarze, Gil Awada, Jens Tijtgat, Freya Vaeyens, Cleo Bertels, Wietse Geens, Samuel Klein, Laura Seynaeve, Louise Cras, Nicky D'Haene, Alex Michotte, Ben Caljon, Isabelle Salmon, Michael Bruneau, Mark Kockx, Sonia Van Dooren, Anne-Marie Vanbinst, Hendrik Everaert, Ramses Forsyth, Bart Neyns
Summary: In this phase I clinical trial, intracerebral administration of NIVO and IPI following maximal safe resection of recurrent glioblastoma was found to be feasible, safe, and associated with encouraging overall survival outcomes when compared to historical cohorts. No significant difference was found in terms of progression-free survival.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Joel Guigay, Keun-Wook Lee, Manish R. Patel, Amaury Daste, Deborah J. Wong, Sanjay Goel, Michael S. Gordon, Martin Gutierrez, Ani Balmanoukian, Christophe Le Tourneau, Alain Mita, Damien Vansteene, Ulrich Keilholz, Patrick Schoffski, Hans Juergen Grote, Dongli Zhou, Marcis Bajars, Nicolas Penel
Summary: In a study of patients with recurrent/metastatic SCCHN, avelumab demonstrated clinical activity with a low rate of severe treatment-related adverse events.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Birgit Geoerger, Lynley Marshall, Karsten Nysom, Guy Makin, Eric Bouffet, Anne-Sophie Defachelles, Loredana Amoroso, Isabelle Aerts, Pierre Leblond, Paulette Barahona, Kim Van-Vlerken, Eric Fu, Flavio Solca, Robert M. Lorence, David S. Ziegler
Summary: This study assessed the safety, pharmacokinetics, and preliminary antitumor activity of afatinib in pediatric patients with cancer. Results showed that afatinib had limited efficacy in pediatric tumors, but it may be effective in patients with specific mutations.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Marie Jose Kersten, Karima Amaador, Monique C. Minnema, Josephine M. I. Vos, Kazem Nasserinejad, Marcel Kap, Efstathios Kastritis, Maria Gavriatopoulou, Willem Kraan, Martine E. D. Chamuleau, Dries Deeren, Lidwine W. Tick, Jeanette K. Doorduijn, Fritz Offner, Lara H. Boehmer, Roberto D. Liu, Steven T. Pals, Meletios A. Dimopoulos
Summary: This study investigated the efficacy and toxicity of the combination of oral proteasome inhibitor ixazomib and rituximab in patients with relapsed Waldenstrom's macroglobulinemia (WM). The results showed promising efficacy with manageable toxicity, suggesting the potential use of this combination therapy for relapsed or refractory WM patients.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Hematology
Faith Davies, Robert Rifkin, Caitlin Costello, Gareth Morgan, Saad Usmani, Rafat Abonour, Antonio Palumbo, Dorothy Romanus, Roman Hajek, Evangelos Terpos, Dasha Cherepanov, Dawn Marie Stull, Hui Huang, Xavier Leleu, Jesus Berdeja, Hans C. Lee, Katja Weisel, Michael Thompson, Mario Boccadoro, Jeffrey Zonder, Gordon Cook, Noemi Puig, Jorge Vela-Ojeda, Eileen Farrelly, Aditya Raju, Marlo Blazer, Ajai Chari
Summary: The study analyzed the effectiveness of different drug combinations in treating refractory multiple myeloma patients, revealing discrepancies between clinical trial results and real-world outcomes, with certain triplet regimens being more common in elderly patients.
ANNALS OF HEMATOLOGY
(2021)
Article
Oncology
Chika Nitani, Junichi Hara, Hiroshi Kawamoto, Tomoaki Taguchi, Toshimi Kimura, Kenichi Yoshimura, Akinobu Hamada, Shigehisa Kitano, Naoko Hattori, Toshikazu Ushijima, Hiromi Ono, Masako Nakamoto, Tsukiko Higuchi, Akihiro Sato
Summary: The aim of this study was to determine the recommended dose of tamibarotene for further research in pediatric and young adult patients with recurrent/refractory solid tumors. The results showed that 12 mg/m(2)/day for 21 days in a 28 day cycle was safe and effective for these patients.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2021)
Article
Oncology
Mariko D. DeWire, Christine Fuller, Olivia Campagne, Tong Lin, Haitao Pan, Tina Young Poussaint, Patricia A. Baxter, Eugene Hwang, Andrew Bukowinski, Kathleen Dorris, Lindsey Hoffman, Angela J. Waanders, Matthias A. Karajannis, Clinton F. Stewart, Arzu Onar-Thomas, Maryam Fouladi, Ira J. Dunkel
Summary: This study investigated the safety and pharmacokinetic properties of ribociclib and everolimus in the treatment of pediatric brain tumors. The results showed that the combination therapy was well-tolerated in children with pharmacokinetic properties similar to those in adults, and potential therapeutic concentrations of ribociclib could be achieved in cerebrospinal fluid and tumor tissue.
CLINICAL CANCER RESEARCH
(2021)
Review
Oncology
Arthur Felix, Pablo Berlanga, Maud Toulmonde, Judith Landman-Parker, Sarah Dumont, Gilles Vassal, Marie-Cecile Le Deley, Nathalie Gaspar
Summary: This review analyzed recurrent/refractory ES phase-I/II trials and found that the majority of trials used single-arm design, mainly testing single drugs, and few trials were international. The results support the need to develop international randomized phase-II trials with progression-free survival as the primary endpoint.
Article
Oncology
Didier Frappaz, Marc Barritault, Laure Montane, Florence Laigle-Donadey, Olivier Chinot, Emilie Le Rhun, Alice Bonneville-Levard, Andreas F. Hottinger, David Meyronnet, Anne-Sophie Bidaux, Gwenaele Garin, David Perol
Summary: The study evaluated the treatment of SHH recurrent/refractory adult medulloblastoma with vismodegib + temozolomide and found no improvement in 6-month progression-free survival. Further refinements are needed for predicting sensitivity to vismodegib.
Article
Oncology
Victor Moreno, Desamparados Roda, Joanna Pikiel, Jose Trigo, Joaquim Bosch-Barrera, Yvette Drew, Rebecca Kristeleit, Sandrine Hiret, David L. Bajor, Patricia Cruz, J. Thaddeus Beck, Srimoyee Ghosh, Christine Dabrowski, Grace Antony, Tao Duan, Jennifer Veneris, Eleftherios Zografos, Janakiraman Subramanian
Summary: Dostarlimab showed promising antitumor activity in patients with recurrent/advanced NSCLC, including all PD-L1 subgroups, and had an acceptable safety profile.
CLINICAL LUNG CANCER
(2022)
Article
Clinical Neurology
Jonathan Metts, Brittany Harrington, Emad Salman, Scott M. Bradfield, Jennifer Flanary, Maua Mosha, Ernest Amankwah, Stacie Stapleton
Summary: The objective of the study was to determine the maximum tolerated dose (MTD) of escalating dose IT combined with a fixed dose of bevacizumab (BIT) in children with relapsed/refractory CNS tumors. Results showed that at the MTD, BIT therapy was well tolerated and prolonged treatment courses of up to 24 cycles were feasible, with radiographic responses observed. Further evaluation is needed for efficacy in a phase II trial.
CHILDS NERVOUS SYSTEM
(2022)
Article
Oncology
Matthew R. Schuelke, Justin H. Gundelach, Matt Coffey, Emma West, Karen Scott, Derek R. Johnson, Adel Samson, Alan Melcher, Richard G. Vile, Richard J. Bram
Summary: This study reports a phase I trial evaluating the safety and immunologic responses to sargramostim/pelareorep in pediatric patients with recurrent or refractory high-grade brain tumors. The results showed that sargramostim/pelareorep had no significant treatment effect on the patients, but caused some adverse events. Although there are limitations to this study, it is of certain importance for the treatment research of pediatric brain tumors.
NEURO-ONCOLOGY ADVANCES
(2022)
Article
Oncology
Beata Holkova, Adriana Zingone, Maciej Kmieciak, Prithviraj Bose, Ashraf Z. Badros, Peter M. Voorhees, Rachid Baz, Neha Korde, Hui-Yi Lin, Jin-Qiu Chen, Michelle Herrmann, Liqiang Xi, Mark Raffeld, Xiuhua Zhao, Wen Wan, Mary Beth Tombes, Ellen Shrader, Caryn Weir-Wiggins, Heidi Sankala, Kevin T. Hogan, Austin Doyle, Christina M. Annunziata, Martha Wellons, John D. Roberts, Daniel Sullivan, Ola Landgren, Steven Grant
CLINICAL CANCER RESEARCH
(2016)
Article
Oncology
Beata Holkova, Maciej Kmieciak, Prithviraj Bose, Victor Y. Yazbeck, Paul M. Barr, Mary Beth Tombes, Ellen Shrader, Caryn Weir-Wiggins, April D. Rollins, Erin M. Cebula, Emily Pierce, Megan Herr, Heidi Sankala, Kevin T. Hogan, Wen Wan, Changyong Feng, Derick R. Peterson, Richard I. Fisher, Steven Grant, Jonathan W. Friedberg
LEUKEMIA & LYMPHOMA
(2016)
Article
Oncology
Beata Holkova, Victor Yazbeck, Maciej Kmieciak, Prithviraj Bose, Shuo Ma, Amy Kimball, Mary Beth Tombes, Ellen Shrader, Wen Wan, Caryn Weir-Wiggins, Amanda Singh, Kevin T. Hogan, Sarah Conine, Heidi Sankala, John D. Roberts, Thomas C. Shea, Steven Grant
LEUKEMIA & LYMPHOMA
(2017)
Article
Hematology
Ashley N. Miller, Ashley Glode, Kathy R. Hogan, Christine Schaub, Cindy Kramer, Robert K. Stuart, Luciano J. Costa
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
(2011)
Article
Hematology
Jeremy Meier, Catherine Roberts, Kassi Avent, Allison Hazlett, Jennifer Berrie, Kyle Payne, David Hamm, Cindy Desmarais, Catherine Sanders, Kevin T. Hogan, Kellie J. Archer, Masoud H. Manjili, Amir A. Toor
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
(2013)
Article
Hematology
Mark Levis, Farhad Ravandi, Eunice S. Wang, Maria R. Baer, Alexander Perl, Steven Coutre, Harry Erba, Robert K. Stuart, Michele Baccarani, Larry D. Cripe, Martin S. Tallman, Giovanna Meloni, Lucy A. Godley, Amelia A. Langston, Sergio Amadori, Ian D. Lewis, Arnon Nagler, Richard Stone, Karen Yee, Anjali Advani, Dan Douer, W. Wiktor-Jedrzejczak, Gunnar Juliusson, Mark R. Litzow, Stephen Petersdorf, Miguel Sanz, Hagop M. Kantarjian, Takashi Sato, Lothar Tremmel, Debra M. Bensen-Kennedy, Donald Small, B. Douglas Smith
Article
Hematology
Stephen H. Petersdorf, Kenneth J. Kopecky, Marilyn Slovak, Cheryl Willman, Thomas Nevill, Joseph Brandwein, Richard A. Larson, Harry P. Erba, Patrick J. Stiff, Robert K. Stuart, Roland B. Walter, Martin S. Tallman, Leif Stenke, Frederick R. Appelbaum
Article
Biophysics
L. J. Costa, J. Abbas, K. R. Hogan, C. Kramer, K. McDonald, C. D. Butcher, A. Littleton, K. Shoptaw, Y. Kang, R. K. Stuart
BONE MARROW TRANSPLANTATION
(2012)
Article
Oncology
Beata Holkova, Maciej Kmieciak, E. Brent Perkins, Prithviraj Bose, Rachid C. Baz, G. David Roodman, Robert K. Stuart, Viswanathan Ramakrishnan, Wen Wan, Cody J. Peer, Jana Dawson, Loveleen Kang, Connie Honeycutt, Mary Beth Tombes, Ellen Shrader, Caryn Weir-Wiggins, Martha Wellons, Heidi Sankala, Kevin T. Hogan, A. Dimitrios Colevas, L. Austin Doyle, William D. Figg, Domenico Coppola, John D. Roberts, Daniel Sullivan, Steven Grant
CLINICAL CANCER RESEARCH
(2014)
Letter
Hematology
Luciano J. Costa, Jonathan Abbas, Karen L. Ortiz-Cruz, Yubin Kang, Robert K. Stuart
EUROPEAN JOURNAL OF HAEMATOLOGY
(2012)
Editorial Material
Pharmacology & Pharmacy
Jonathan A. Abbas, Robert K. Stuart
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2012)
Article
Oncology
Stefan Faderl, Meir Wetzler, David Rizzieri, Gary Schiller, Madan Jagasia, Robert Stuart, Siddhartha Ganguly, David Avigan, Michael Craig, Robert Collins, Michael Maris, Tibor Kovacsovics, Stuart Goldberg, Karen Seiter, Parameswaran Hari, Jochen Greiner, Norbert Vey, Christian Recher, Farhad Ravandi, Eunice S. Wang, Michael Vasconcelles, Dirk Huebner, Hagop M. Kantarjian
JOURNAL OF CLINICAL ONCOLOGY
(2012)
Article
Oncology
Charles Butler, Daynna J. Wolff, Yubin Kang, Robert K. Stuart, Luciano J. Costa
LEUKEMIA & LYMPHOMA
(2012)
Article
Hematology
Luciano J. Costa, Cindy Kramer, Kathy R. Hogan, Coleen D. Butcher, Amanda L. Littleton, Katie B. Shoptaw, Yubin Kang, Robert K. Stuart
Article
Oncology
Alice Mims, Robert K. Stuart
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
(2013)